The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in previously untreated advanced squamous non–small cell lung cancer: Overall survival results of the phase 3 HARMONi-6 trial.
 
Chen Zhiwei
No Relationships to Disclose
 
Fang Yang
No Relationships to Disclose
 
Yongzhong Luo
No Relationships to Disclose
 
Longhua Sun
No Relationships to Disclose
 
Lin Wu
No Relationships to Disclose
 
Zhengxiang Han
No Relationships to Disclose
 
Yun Fan
No Relationships to Disclose
 
Yanqiu Zhao
No Relationships to Disclose
 
XingYa Li
No Relationships to Disclose
 
Haipeng Xu
No Relationships to Disclose
 
Xiangjiao Meng
No Relationships to Disclose
 
Ying Liu
No Relationships to Disclose
 
Zhiye Zhang
No Relationships to Disclose
 
Hui Luo
No Relationships to Disclose
 
Qin Shi
No Relationships to Disclose
 
Xuelei Ma
No Relationships to Disclose
 
Xuezhen Ma
No Relationships to Disclose
 
Zhongmin Zhang
No Relationships to Disclose
 
Michelle Xia
Employment - Akeso Biopharma, Inc., Zhongshan, China
 
Shun Lu
Leadership - Innovent BIOLOGICS, INC; Shanghai Fosun; Simcere Zaiming
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; GenomiCare; Hutchison MediPharma; InventisBio Co. Ltd; Menarini; Pfizer; Roche; Simcere; Yuhan; Zai Lab
Speakers' Bureau - AstraZeneca; Hansoh Pharma; Hengrui Therapeutics; Roche
Research Funding - AstraZeneca (Inst); BeiGene (Inst); BMS (Inst); Hansoh (Inst); Hengrui Therapeutics (Inst); Hutchison MediPharma (Inst); Lilly Suzhou Pharmaceutical Co. (Inst); Roche (Inst)